Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

rage us as we proceed expeditiously through our ongoing Phase 2 program."

Phase 1b Clinical Trial Design

This 14 day randomized, double-blind, placebo-controlled, sequential-group study of ascending multiple doses enrolled subjects with chronic HCV infection who were naive to treatment. Subjects were enrolled in sequential, ascending dose cohorts with a target of 16 subjects (12 subjects receiving HCV-796 BID and 4 receiving placebo in each cohort). The first cohorts assessed the effect of HCV-796 as monotherapy compared to placebo (data from which were released on November 10, 2005). Subsequent cohorts were comprised of subjects who received peg-IFN (PEG-Intron; 1.5 ug/kg/dose) on days -1 and 7 in combination with either placebo or HCV-796 (100 mg, 250 mg, 500 mg or 1000 mg) every 12 hours, from days 1 to 14.

Antiviral Activity Results

Data are available through treatment day 14 from subjects in four combination treatment groups (n= 10 to 12 subjects per group) and on 19 subjects who received peg-IFN alone.

-- For genotype 1, mean reduction from baseline ranged from 1.5 to 2.3 log10 on day 7 and from 2.6 to 3.2 log10 on day 14 in the combination therapy groups compared to 0.9 log10 on day 7 and 1.3 log10 on day 14 for peg-IFN alone.

-- For non-genotype 1, mean reduction from baseline ranged from 2.8 to 3.5 log10 on day 7 and from 3.5 to 4.8 log10 on day 14 in the combination therapy groups compared to 1.5 log10 on day 7 and 2.6 log10 on day 14 for peg-IFN alone.

-- Viral reduction greater or equal to 2.0 log10 at day 14 was achieved in 70 to 92 percent of subjects in all combination groups compared to 40 percent on peg-IFN alone.

-- At day 14, 30 to 33 percent of patients in the combination groups receiving greater than or equal to 250 mg BID of HCV-796 achieved viral levels below the quantification limit of 50 IU/mL HCV RNA.

Safety and Tolerability Results

A safety review of HCV-796 in combinati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/16/2009)... -- Scientists at,deCODE genetics, Inc. (Nasdaq: DCGN ) ... version of a common single-letter variant in the ... impact on susceptibility to type 2,diabetes (T2D). The ... large, but unusual:,if an individual inherits it from ... more than 30% compared to those who inherit ...
(Date:12/16/2009)... Cohera Medical Inc. today announced the treatment of ... lead surgical adhesive product, TissuGlu®. Initiation of the ... progression of the lead product toward clinical practice. ... open-label, randomized study to investigate the safety of ... associated complications in abdominoplasty, or "tummy tuck," surgeries. ...
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
Breaking Medicine Technology:deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3CareCentrix Receives URAC Health Utilization Management Accreditation 213 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 113 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 2Red Cross Strives to Help Disasters Vulnerable Population 59839 1Red Cross Strives to Help Disasters Vulnerable Population 59839 2Red Cross Strives to Help Disasters Vulnerable Population 59839 3Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 1Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 2
... presented at ICAAC -, BRIDGEWATER, N.J., Sept. ... open-label Phase 3 study showed that 84 percent ... of,PREZISTA(TM) (darunavir) 800 mg (two 400 mg tablets) ... and tenofovir disoproxil,fumarate) reached an undetectable viral load ...
... 18 - A,multi-disciplinary group of researchers from the ... Maryland Biotechnology Institute (UMBI),has won a competitive, $2 ... way researchers develop and test pharmaceutical drugs., ... Distinguished,Professor and chair of the Fischell Department of ...
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a leading global ... its portfolio companies, Acclarent, Inc., has entered into ... Inc., a Johnson & Johnson company, in an ... estimated cash on hand at time of closing). ... and commercializing devices that address conditions affecting the ...
(Date:12/16/2009)... benefit from breakthroughs, experts say, , , WEDNESDAY, Dec. 16 ... used for research come mostly from white donors, a ... non-whites will benefit less from any medical breakthroughs that ... , Blacks could be especially affected. In fact, none ... showed any traces of recent African ancestry, the team ...
(Date:12/16/2009)... Losing has never felt so good for "The Biggest ... lifestyle means continuing to make smart choices everyday to ... one healthy choice that is an important part of ... take. Every glass of milk has nine essential nutrients ... normal blood pressure, and calcium and vitamin D for ...
(Date:12/16/2009)... LAUREL, Md., Dec. 16 For ... Army Medical Center in Washington, D.C., the holidays can ... aren,t able to travel home rely more than ever ... friends. This week, calling home just got easier ... in free calling cards, which will provide hundreds of ...
(Date:12/16/2009)... 16 As a result of C3: Colorectal ... peer reviewed cancer research program is included in the ... This new cancer research program will research cancers, like ... prostate, lung and ovarian cancer research programs run by ... ,, The $15 million in funding for this ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3
... disorders makes prevention more difficult, study finds, , , FRIDAY, ... who commit suicide have been diagnosed with a mental ... their death certificates list mental disorder as a contributing ... make it more difficult for health-care policymakers to create ...
... than those who didn,t, study shows , , FRIDAY, April ... for some good, hearty laughter could help diabetics improve ... heart attack, researchers report. , "Laughter may indeed be ... preventive care specialist and psychoneuroimmunologist at Loma Linda University ...
... United States Great Depression of 1929 has the American ... well-being across the parameters of occupational, spiritual, emotional, and ... people are at risk for suffering lowered self esteem, ... St. Thomas University Counseling Programs - initiated ...
... April 17 Chiltern International Limited (Chiltern), a global Clinical ... Europe, the Americas and India, today announced the acquisition of ... Paulo, Brazil.Established in 1999 by Eduardo ... Halke r , BSN, Vigiun has ...
... 17 Medication mistakes at home have created a ... study, and the need for a new approach to ... Pharm and co-owner of Reeves-Sain.Reeves said we need to ... a clearer, more easily managed system, and his company ...
... Bertalan Mesko, medical blogger and health 2.0 consultant ... a video site designed to present echocardiology videos for ... of one of the most famous medical blogs, Medgadget.com. ... of other video sharing sites, including easy uploading, comments ...
Other Medicine News:Health News:Death Certificates Incomplete for Suicide Victims 2Health News:Laughter May Lower Heart Attack Risk in Diabetics 2Health News:Laughter May Lower Heart Attack Risk in Diabetics 3Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Chiltern Acquires Brazil-Based Clinical Research Organization Vigiun 2Health News:Medication Mismanagement Is a Growing Danger 2
All Day Comfort for the Lower Body...
All Purpose, General Procedure Apron...
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: